Page contentsPage contents Key facts Decision Key facts Active substance Nipocalimab Therapeutic area Neurology Decision number P/0509/2022 PIP number EMEA-002559-PIP06-22 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of chronic inflammatory demyelinating polyradiculoneuropathy Route(s) of administration Subcutaneous use Contact for public enquiries Janssen Cilag International NV Tel. +3214602111E-mail: contact@Janssen-emea.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 02/12/2022 Compliance check done No Decision P/0509/2022 : EMA decision of 2 December 2022 on the granting of a product specific waiver for nipocalimab (EMEA-002559-PIP06-22)Reference Number: EMA/898521/2022 English (EN) (207.96 KB - PDF)First published: 10/11/2023 View Share this page